New US study reveals key reasons why millions of people with obesity are not receiving adequate care
- Details
- Category: Novo Nordisk
Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In Obesity Management (ACTION) Study published in Obesity,(2) the official journal of The Obesity Society.
FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
- Details
- Category: AstraZeneca
AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Calquence (acalabrutinib). Calquence is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology therapies. The new effort combines Boehringer Ingelheim's oncology research and Sarah Cannon’s expertise in clinical trial design and recruitment to evaluate BI 891065, a novel and potent SMAC mimetic, alone and as a potential combination partner with PD-1-directed cancer therapy.
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
- Details
- Category: Novartis
Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera® (177Lu-DOTATATE),
Merck announces recipients of €1 million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced recipients of the fifth annual Grant for Multiple Sclerosis Innovation (GMSI) during the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. This year, 77 proposals from 25 countries were submitted, representing innovative research projects taking place across the globe.
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
- Details
- Category: Novartis
Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting (October 25-28, 2017 Paris, France).
BIOCAD enters the European market
- Details
- Category: Business
The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. These are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.
More Pharma News ...
- Roche reports strong sales growth in the first nine months of 2017
- The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries
- A great place to do great things: Developing game-changing technology at Abbott
- MSD Innovation Factory is looking for digital solutions for anaesthesiologists
- Merck brings customers closer to gene therapy product commercialization
- FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
- FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review